Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
28 Dec 2017 Social This is the single best source on Biologics for Patients - Download the Patient Guide to Biologics from RheumNow. 6 pages of overview/comparisons; 5 biologic handouts https://t.co/D80f7I6Sr7
21 Aug 2017 Social Ironwood announces FDA approval of its combo drug lesinurad/allopurinol in a 200/300 tablet. Could this be useful? https://t.co/lcUZTieKqg
09 Nov 2018 Social Frankincense is derived from Boswellia plants. Boswellia serrata is an Ayurvedic purported to be anti-inflammatory; inhibits 5-lipoxygenase & possibly prostaglandins, Pilot studies in OA have shown significant pain relief and improved physical function https://t.co/OPxal73aIF
09 Aug 2019 Social Amgen wins U.S. patent battle against Novartis over Enbrel patents, delaying Novartis' attempts to launch its etanercept biosimilar Erelzi until (possibly) 2029. Novartis intends to appeal. https://t.co/uoEQJJUf9A
12 Apr 2017 Social Looking for PATIENT Views on BIOSIMILAR BIOLOGIC Drugs - They're new, how will they affect you. Patients vote at>> https://t.co/tkXOvwzkpq
29 Mar 2018 Social Large BSRBR study of Serious infections w/ biologics shows SI=5.51 per 100PY for all; tocilizumab was higher vs ETN (HR 1.22; 1.02 to 1.47) & certolizumab lower or equal to ETN. 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%). https://t.co/h5BieShHpH
20 Mar 2016 Social Tofacitinib meets primary endpoints in ulcerative colitis trials, achieving 16-18% remission rates https://t.co/mkWZTfz213
29 Nov 2016 Social Good, basic overview of Biosimilars. https://t.co/N0hE8xL8Ga
03 May 2018 Social Sandoz biosimilar version of rituximab set back by a complete response letter from the FDA delaying development of their RTX biosimilar; same recent fate as Celltrions RTX biosimilar. https://t.co/EkikDMU1u8
20 Oct 2017 Social RT @emartinmola: High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar https://t.co/IenWgRZUQL
14 Dec 2016 Social IL-33 a biomarker for RTX response - if RA pts are RF+ or CCP+; w/ detectable serum IL-33 & High IgG levels. https://t.co/meig18rSEX
12 Nov 2019 Social RT @philipcrobinson: Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co…
11 Dec 2019 Social Biosimilar Tote-Board in Rheumatology: 4 Infliximab biosimilars - Inflectra, Renflexis, Ifixi, Avsola 5 Adalimumab biosimilars - Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada 2 Etanercept biosimilars - Erelzi, Enticovo 2 Rituximab biosimilars - Truxima, Ruxience
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response https://t.co/rLn6aJowry
13 Jun 2018 Social RT @FerreiraRJO: Excellent talk from Tracy French about how nurses can promote shared decision making with patients being proposed to switc…
07 Nov 2017 Social RT @DrPetryna: #16L #acr17 no risk of DVTorPE w/Tofa from RTC trials analysis. IRs comparable to #corona data for Tofa&cDMARDs @RheumNow ht…
06 Jun 2016 Social Did you know that many (not all) biologics have latex? Dr. Dao writes how to Handle Latex Allergies w/ Biologics https://t.co/ToK3AmcAoX
13 Feb 2020 Social RT @Janetbirdope: Adalimumab seeems better than infliximab Behcet’s uveitis. Alvin Wells #RWCS2020 @RheumNow https://t.co/dYrKyNjASB
22 Jul 2016 Social In Tofacitinib RCTs 1821 child-bearing age F exposed; 47 pregnant (33 monoRx). 1 Pulm valve stenosis, 7 Spont Abs. https://t.co/O2GT1BKiMT
14 Sep 2018 Social FDA approves SC Actemra (tocilizumab) for systemic JIA (Still's disease) +/-MTX. IV TCZ was FDA approved In 2011 for SJIA. Approval is based on JIGSAW, a 52-wk study. sJIA dosing based on Weight ( <30 kg-162 mg q2wk; ≥30 162 mg qwk) https://t.co/kWXdwAh35Z